XW 001
Alternative Names: XW-001Latest Information Update: 28 Mar 2025
At a glance
- Originator Sciwind Biosciences
- Class Antifibrotics; Antivirals; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Respiratory syncytial virus infections
- No development reported Pulmonary fibrosis
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for preclinical development in Pulmonary-fibrosis in China (PO)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in China (Inhalation)
- 21 Aug 2023 Sciwind Biosciences withdraws a phase II trial in Covid 19 infections in Argentina and Peru (Inhalaton) (NCT05083117)